[1]孙佳,刘亚楠.非小细胞肺癌组织中lncRNA DGCR5、BRCA1、TIM-1表达与患者临床病理特征和预后相关性研究[J].陕西医学杂志,2026,(2):273-277,284.[doi:DOI:10.3969/j.issn.1000-7377.2026.02.024]
　SUN Jia,LIU Yanan.Correlation between the expression of lncRNA DGCR5,BRCA1 and TIM-1 in non-small cell lung cancer tissue and the clinicopathological characteristics and prognosis of patients[J].,2026,(2):273-277,284.[doi:DOI:10.3969/j.issn.1000-7377.2026.02.024]
点击复制

非小细胞肺癌组织中lncRNA DGCR5、BRCA1、TIM-1表达与患者临床病理特征和预后相关性研究

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2026年2期
页码:
273-277,284
栏目:
临床病理
出版日期:
2026-02-05

文章信息/Info

Title:
Correlation between the expression of lncRNA DGCR5,BRCA1 and TIM-1 in non-small cell lung cancer tissue and the clinicopathological characteristics and prognosis of patients
作者:
孙佳1; 刘亚楠2
（1.大庆市人民医院 哈尔滨医科大学附属第五医院呼吸与危重症医学科，黑龙江 大庆 163316；2.大庆市人民医院 哈尔滨医科大学附属第五医院肿瘤科，黑龙江 大庆 163316）
Author(s):
SUN Jia1; LIU Yanan2
(1.Department of Respiratory and Critical Care Medicine,Daqing People’s Hospital,Daqing 163316,China;2.Department of Oncology,Daqing People’s Hospital,Daqing 163316,China)
关键词:
非小细胞肺癌; 长链非编码RNA DiGeorge综合征关键区域基因5; 乳腺癌易感基因1; T细胞免疫球蛋白及黏蛋白结构域分子-1; 临床病理特征; 预后; 相关性
Keywords:
Non-small cell lung cancer; Long non-coding RNA DiGeorge syndrome critical region gene 5; Breast cancer susceptibility gene 1; T cell immunoglobulin and mucin-domain containing molecule-1; Clinicopathological characteristics; Prognosis; Correlation
分类号:
R 734.2
DOI:
DOI:10.3969/j.issn.1000-7377.2026.02.024
文献标志码:
A
摘要:
目的：探讨非小细胞肺癌（NSCLC）组织中长链非编码RNA（lncRNA）DiGeorge综合征关键区域基因5（DGCR5）、乳腺癌易感基因1（BRCA1）、T细胞免疫球蛋白及黏蛋白结构域分子-1（TIM-1）表达与患者临床病理特征和预后的相关性。方法：选取NSCLC患者120例，术中收集患者癌组织及癌旁组织标本，比较组织中lncRNA DGCR5、BRCA1、TIM-1表达，分析癌组织中三者表达与患者临床病理特征的关系。随访3年，分析lncRNA DGCR5及BRCA1、TIM-1蛋白表达与患者3年生存率的关系。多因素Cox回归分析NSCLC患者预后的影响因素。结果：与癌旁组织比较，NSCLC组织中TIM-1蛋白阳性表达率升高，lncRNA DGCR5表达水平、BRCA1蛋白阳性表达率降低（均P＜0.05）。NSCLC组织中lncRNA DGCR5、BRCA1、TIM-1表达与TNM分期、淋巴结转移、肿瘤分化程度有关（均P＜0.05）。lncRNA DGCR5低表达患者3年生存率低于高表达患者，BRCA1阴性患者3年生存率低于BRCA1阳性患者，TIM-1阳性患者3年生存率低于TIM-1阴性患者（均P＜0.05）。NSCLC患者3年内生存的危险因素为肿瘤低分化、淋巴结转移、TNM分期Ⅲ期、lncRNA DGCR5低表达、BRCA1蛋白阴性表达、TIM-1蛋白阳性表达（均P＜0.05）。结论：NSCLC组织中lncRNA DGCR5、BRCA1、TIM-1异常表达，且三者与NSCLC患者临床病理特征及预后有关。
Abstract:
Objective:To investigate the correlation between the expression of long non-coding RNA DiGeorge syndrome critical region gene 5 (lncRNA DGCR5),breast cancer susceptibility gene 1 (BRCA1),and T cell immunoglobulin and mucin-domain containing molecule-1 (TIM-1) in non-small cell lung cancer (NSCLC) tissue and the clinicopathological characteristics and prognosis of patients.Methods：A total of 120 patients with NSCLC were enrolled.Cancer tissue and adjacent non-cancerous tissue specimens were collected during surgery,and the expression levels of lncRNA DGCR5,BRCA1 and TIM-1 were compared.The relationships between the expression of these three factors in cancerous tissues and the clinicopathological characteristics of patients were analyzed.Patients were followed up for 3 years,and the relationship between the expression of lncRNA DGCR5,BRCA1,and TIM-1 and the 3-year survival rate was analyzed.Multivariate Cox regression was used to identify independent prognostic factors.Results:Compared with adjacent non-cancerous tissues,NSCLC tissues showed increased positive expression rate of TIM-1 protein and decreased expression levels of lncRNA DGCR5 and positive expression rate of BRCA1 protein (all P<0.05).The expression of lncRNA DGCR5,BRCA1 and TIM-1 in NSCLC tissues was significantly associated with TNM stage,lymph node metastasis,and tumor differentiation degree (all P<0.05).Patients with low expression of lncRNA DGCR5 had a lower 3-year survival rate than those with high expression;patients with negative BRCA1 expression had a lower survival rate than those with positive expression;and patients with positive TIM-1 expression had a lower survival rate than those with negative expression (all P<0.05).Poor tumor differentiation,lymph node metastasis,TNM stage Ⅲ,low expression of lncRNA DGCR5,negative BRCA1 protein expression,and positive TIM-1 protein expression were identified as risk factors for 3-year survival in NSCLC patients (all P < 0.05).Conclusion:The abnormal expression of lncRNA DGCR5,BRCA1 and TIM-1 in NSCLC tissues is closely related to the clinicopathological characteristics and prognosis of NSCLC patients.

参考文献/References:

[1]WHITE B,HARRIS M,VILLACORTA R,et al.Cost-effectiveness of perioperative nivolumab+neoadjuvant platinum doublet chemotherapy as treatment for resectable non-small cell lung cancer in the United States[J].J Med Econ,2025,28(1)：625-637.
[2]ROTH J A,KRATOCHVIL D,DORMAN S,et al.Cost-efficiency and expanded access modeling of conversion to biosimilar bevacizumab in metastatic colorectal and non-squamous non-small cell lung cancer in Medicare[J].J Med Econ,2025,28(1)：378-386.
[3]吴保钦,王寅飞,李建伟.MiRNA和lncRNA在非小细胞肺癌中作用的研究进展[J].生理科学进展,2024,55(1)：51-58.
[4]张玲,徐海燕,王强力,等.三阴性乳腺癌组织中lncRNA HCG11 mRNA和miR-4465水平表达与临床病理特征及预后的相关性研究[J].现代检验医学杂志,2025,40(1)：84-89.
[5]张静,李唯源,胡国志,等.miR-199a-3p通过调控BRCA1影响小细胞肺癌细胞对阿帕替尼敏感性的研究[J].检验医学与临床,2025,22(6)：760-767.
[6]谯钰琪,惠盼,董济民,等.TIM-3表达与非小细胞肺癌预后及临床病理特征关系的meta分析[J].国际呼吸杂志,2022,42(21)：1627-1634.
[7]中华医学会肿瘤学分会,中华医学会杂志社.中华医学会肺癌临床诊疗指南(2022版)[J].中华肿瘤杂志,2022,44(6)：457-490.
[8]熊辉.电视胸腔镜微创手术治疗老年非小细胞肺癌患者的有效性和安全性研究[J].实用心脑肺血管病杂志,2018,26(6)：45-47,52.
[9]CHOUAID C,GIANNOPOULOU A,STARRY A,et al.The impact of KRAS mutational status on patient-reported outcomes in advanced non-small-cell lung cancer：A cross sectional study in France and Germany[J].J Med Econ,2025,28(1)：13-24.
[10]苏凯,俞庆华,曹家旺,等.非小细胞肺癌血清lncRNA XIST、miR-126-3p表达与根治术后复发的关系[J].局解手术学杂志,2025,34(2)：134-139.
[11]李菲凡,向俊馨,刘佳慧,等.LncRNA FEZF1-AS1通过miR-130a-5p/CCND1轴促进非小细胞肺癌发展的分子机制研究[J].南方医科大学学报,2024,44(5)：841-850.
[12]郭伟峰,何约明,庄锡彬,等.非小细胞肺癌不同胸腔积液严重程度及预后患者lncRNA MEG3表达及其与Th17/CD4+T细胞的关系[J].中国免疫学杂志,2024,40(10)：2091-2094,2100.
[13]白云波,张振华,范志刚.lncRNA DGCR5在非小细胞肺癌组织中的表达及其与临床病理特征的相关性分析[J].现代生物医学进展,2023,23(2)：396-400.
[14]孔德光,杨艳,余维巍.lncRNA MALAT1调控GPx3去甲基化参与非小细胞肺癌的发生发展[J].华中科技大学学报（医学版）,2024,53(5)：569-577.
[15]范喜瑞,戚之琳,邓园洁,等.LncRNA MAGI2-AS3通过靶向调控miR-1269a/PTEN/AKT通路增强非小细胞肺癌对顺铂化疗的敏感性[J].南方医科大学学报,2024,44(10)：2033-2043.
[16]薛春霞,梁建庆,张媛媛,等.基于lncRNA H19/miR-19b3p/FTH1轴探讨归芪益元膏联合顺铂对Lewis肺癌小鼠的干预效应及机制[J].中国中医药信息杂志,2024,31(8)：90-96.
[17]廖兴宇,刘慧敏,孙洁,等.BRCA1/2突变HER2阳性乳腺癌的临床特征及其对新辅助靶向治疗的反应[J].肿瘤防治研究,2025,52(6):491-495.
[18]沈洋,李长芬,李海龙,等.HER-2、BRCA1/2在三阴性乳腺癌组织中的表达及与临床病理参数、预后的相关性研究[J].诊断病理学杂志,2025,32(7):780-786.
[19]吴天秀,徐瑜,廖秀清,等.驱动基因阴性Ⅲ/Ⅳ期非小细胞肺癌BRCA1/2基因突变与含铂化疗疗效的关系[J].中华肺部疾病杂志:电子版,2023,16(5)：615-623.
[20]杨茜,赵洁,唐海涛,等.非小细胞肺癌同源重组修复通路基因与临床特征的相关性分析[J].重庆医科大学学报,2024,49(7)：871-876.
[21]TAN T,YUAN S,CHU W,et al.Low-dose anlotinib plus immune checkpoint inhibitors offers better efficacy and safety in advanced non-small cell lung cancer treatment[J].Anticancer Drugs,2025,36(5)：408-414.
[22]陈娟,郭金莲,周慧会,等.长链非编码RNASUCLG2-AS1通过调节微小RNA-491-5p对非小细胞肺癌细胞增殖和免疫逃逸的影响[J].陕西医学杂志,2024,53(7)：884-889.
[23]任明智,王涛.西格列汀调节Hippo/Yes相关蛋白信号通路对非小细胞肺癌A549/CDDP细胞增殖、迁移、凋亡与化疗敏感性的影响实验研究[J].陕西医学杂志,2024,53(12)：1599-1603,1610.
[24]阚书慧,张丹.温阳益髓方联合直接灸四花穴对非小细胞肺癌化疗所致骨髓抑制患者免疫功能及肿瘤相关抗原的影响[J].陕西中医,2024,45(2)：200-203.
[25]朱文娣,李侠,李林蔚,等.吉非替尼联合克唑替尼对非小细胞肺癌患者ERCC1、RRM1和BRCA1表达水平及复发率的影响[J].临床和实验医学杂志,2025,24(20):2140-2144.
[26]李美璇,王倩茹,薛晋玲,等.肺炎支原体肺炎患儿血清PN、Tim-1、CRP联合检测在病情及预后评估中的作用[J].临床肺科杂志,2025,30(7):1040-1045.
[27]董莉,董媛媛,何苗.血miR-192、PD-1、Tim-3及Wnt信号通路相关因子表达情况在梅毒分期中的应用价值评估[J].海军医学杂志,2025,46(8):805-810.
[28]王歆玮,郑源强,张敏,等.T细胞免疫球蛋白和黏蛋白结构域分子1(Tim-1)促进马尔堡病毒感染的作用研究[J].标记免疫分析与临床,2022,29(2):332-336.
[29]周静,黄闯,彭凤玲.人免疫球蛋白联合醋酸泼尼松治疗系统性红斑狼疮的效果及对患者CD28、ICOS、Tim-1表达的影响[J].中国麻风皮肤病杂志,2019,35(6):334-337,341.
[30]江雪,李建文,冯丽春,等.布地奈德联合脾氨肽治疗过敏性鼻炎哮喘综合征患儿的临床效果及对VCAM-1和Tim-1的影响[J].临床误诊误治,2021,34(3):25-30.
[31]王倩,蒋思雨,刘倩希,等.加味麦门冬汤联合安罗替尼治疗晚期驱动基因阴性非小细胞肺癌临床疗效[J].陕西中医,2024,45(8)：1048-1051.
[32]陈灿,郑林鑫,麦玉梅,等.非小细胞肺癌组织中PD-1、TIM-1的表达及其对预后的影响[J].局解手术学杂志,2022,31(4)：319-323.
[33]颜海,何玲娟,黄鑫,等.肿瘤组织中BRCA1和RAP80的表达与非小细胞肺癌铂类化疗预后的相关性研究[J].中国现代应用药学,2022,39(22)：3000-3005.

相似文献/References:

[1]王晓东,景鹏宇△,崔 凯,等.术前外周血中性粒细胞淋巴细胞比值对ⅠⅢ期非小细胞肺癌患者预后的影响[J].陕西医学杂志,2019,(12):1612.
[2]彭 峰,彭奕华,张宏华,等.非小细胞肺癌化疗前后血清糖类抗原125、肿瘤异常蛋白水平变化及其与疗效的关系[J].陕西医学杂志,2020,49(7):851.[doi:DOI:10.3969/j.issn.10007377.2020.07.023]
　PENG Feng,PENG Yihua,ZHANG Honghua,et al.Changes of serum CA125 and TAP levels before and after chemotherapy for non-small cell lung cancer and their relationship with curative effect[J].,2020,49(2):851.[doi:DOI:10.3969/j.issn.10007377.2020.07.023]
[3]杨 昕,刘 芳,杜 静,等.肺癌癌组织中过氧化物酶增殖体激活受体γ基因表达水平对培美曲塞化疗疗效的预测价值*[J].陕西医学杂志,2020,49(10):1359.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.042]
　YANG Xin,LIU Fang,DU Jing,et al.Predictive value of PPARγ gene expression level in lung cancer tissue for curative effect of pemetrexed chemotherapy[J].,2020,49(2):1359.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.042]
[4]王晓东,吕 峰△,崔 凯.ⅢA-N2期非小细胞肺癌纵隔淋巴结跳跃性转移临床特点及对预后的影响[J].陕西医学杂志,2020,49(12):1634.[doi:DOI:10.3969/j.issn.1000-7377.2020.12.025]
[5]苏艳丽,李 波.Th9细胞对非小细胞肺癌患者CD8+T细胞抗肿瘤活性的调控作用[J].陕西医学杂志,2021,50(1):15.[doi:DOI:10.3969/j.issn.1000-7377.2021.01.004]
　SU Yanli,LI Bo.Regulatory of Th9 cells on anti-tumor activity of CD8+T cells in patients with non-small-cell lung cancer[J].,2021,50(2):15.[doi:DOI:10.3969/j.issn.1000-7377.2021.01.004]
[6]岳 英,董锦华,肖月梅.肺免疫微环境中调节因子表达对肿瘤生长和转移的影响[J].陕西医学杂志,2021,50(4):495.[doi:DOI:10.3969/j.issn.1000-7377.2021.04.030]
[7]崔 凯,白峻峰,支亚男,等.外泌体微小RNA-23a对非小细胞肺癌血管生成的影响及机制研究[J].陕西医学杂志,2021,50(9):1048.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.002]
　CUI Kai,BAI Junfeng,ZHI Ya'nan,et al.Effect of exosome miR-23a on angiogenesis in NSCLC and its mechanism[J].,2021,50(2):1048.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.002]
[8]陈 彦,姜立朋.基于CT的影像组学特征对非小细胞肺癌放射治疗效果的评估价值[J].陕西医学杂志,2021,50(9):1094.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.013]
　CHEN Yan,JIANG Lipeng.Evaluation value of CT-based imaging omics features for radiotherapy effect in treatment of non-small cell lung cancer[J].,2021,50(2):1094.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.013]
[9]崔 凯,支亚男,王壮壮,等.微小RNA-30对非小细胞肺癌侵袭、转移能力的影响及机制研究[J].陕西医学杂志,2021,50(10):1214.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.009]
　CUI Kai,ZHI Ya'nan,WANG Zhuangzhuang,et al.Effect and mechanism of miR-30 on invasion and metastasis of non-small cell lung cancer[J].,2021,50(2):1214.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.009]
[10]梁乐乐,王 鹏,刘俊霞,等.非小细胞肺癌组织中T细胞免疫球蛋白区黏蛋白-3、程序性死亡因子-1及程序性因子配体1的表达分析[J].陕西医学杂志,2021,50(10):1227.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.012]
　LIANG Lele,WANG Peng,LIU Junxia,et al.Expression of TIM-3,PD-1 and PD-L1 in non-small cell lung cancer[J].,2021,50(2):1227.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.012]

备注/Memo

备注/Memo:
黑龙江省卫生健康委员会科研课题（20220303021055）
更新日期/Last Update: 2026-02-04